Biological Threat Agents

MRIGlobal’s services span all stages of the diagnostic product development process, beginning with research and development.

Our research, development, testing, and evaluation supporting biological threat agent disease diagnostics includes molecular and immunological assay method and platform development. Our work leads clients through clinical validation, including FDA 510(k), Pre-Market Notification (PMN), and CE Mark Submissions.


We develop assays and protocols related to biological threat disease diagnostics:

Molecular & Immunological

Next Generation Sequencing

Advanced Bioinformatics

Prototype development of sample collection, testing, preservation, and transport solutions for austere, nonconventional, and traditional laboratories

Our Staff

Theresa Seitz prepares a sample for testing on a point-of-care diagnostic device.

MRIGlobal scientists conduct research, development, testing, and evaluation to support biological threat disease diagnostic technology innovation. The goal of this support is to ultimately result in an FDA-cleared product.



Theresa Seitz preparing a sample for testing on a point-of-care diagnostic device

Work with Us

Learn more about how MRIGlobal can test and evaluate your chemical and biological approaches by contacting us.

Contact us to learn more about how we can help with your next endeavor.

Contact Us

See Our Certifications

See Our Facilities